Montpellier, France

Véronique Gire



Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2021-2025

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations in Oncology by Véronique Gire

Introduction

Véronique Gire is a notable inventor based in Montpellier, France. He has made significant contributions to the field of oncology, particularly in the study of cancer stem cells. With two patents to his name, Gire's work focuses on innovative methods for understanding and treating cancer.

Latest Patents

Gire's latest patents include "Delta133P53Beta and Delta133P53Gamma isoforms are biomarkers of cancer stem cells." This invention relates to a method for producing cancer stem cells through the overexpression of Δ133p53β isoform, Δ133p53γ isoform, or both. It also includes a method for predicting the risk that treatment with a chemotherapeutic anti-cancer agent induces cancer stem cells in a subject suffering from cancer. This prediction is based on the detection of an increase in Δ133p53β isoform, Δ133p53γ isoform, or both following treatment. Additionally, the patent discusses therapeutic uses of a combination of chemotherapeutic agents and agents that reduce the expression of these isoforms, as well as screening methods for anti-cancer stem cell agents.

Career Highlights

Gire has worked with prominent institutions such as the Centre National de la Recherche Scientifique and Université de Montpellier. His research has significantly advanced the understanding of cancer biology and treatment strategies.

Collaborations

Some of his notable coworkers include Pierre Roux and Nikola Arsic. Their collaborative efforts have contributed to the development of innovative solutions in cancer research.

Conclusion

Véronique Gire's work exemplifies the intersection of innovation and healthcare, particularly in oncology. His patents and research continue to pave the way for advancements in cancer treatment and understanding.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…